OCU400
Gene Therapy Target: NR2E3
Ocugen, Inc.
Most recent annual filing: 2026-03-04
Pipeline (13 active programs)
OCU410ST
Gene Therapy Target: RORA
OCU410
Gene Therapy Target: RORA
OCU200
Protein Target: integrin receptors
NeoCart
- Knee Cartilage Injuries
OCU500
Gene Therapy Target: SARS-CoV-2 Spike protein
- COVID-19
- Undisclosed indication
OCU510
Gene Therapy Target: influenza
OCU520
Technology platforms
Novel Modifier Gene Therapy Platform · CanSino Biologics
Nuclear hormone receptor (NHR)-based modifier gene therapy platform using AAV5 vector delivery to retinal tissue; targets NR2E3 and RORA to address multiple inherited retinal diseases including retinitis pigmentosa, Stargardt disease, and dry AMD/geographic atrophy with a gene-agnostic approach
Targets: NR2E3, RORA
Inhaled Mucosal Vaccine Platform · Washington University in St. Louis
Next-generation inhalation-based mucosal vaccine platform based on a novel ChAd vector; designed to generate local mucosal immunity in the nasopharyngeal region for respiratory infectious diseases including COVID-19 and influenza
Targets: SARS-CoV-2 Spike protein, influenza
Biotech Distilled coverage (9)
- 2026-05-15 UPDATE: Ocugen (OCGN) – The Greenshoe Gets Pulled, The CMO Walks 🔒 Paid
- 2026-05-06 UPDATE: Ocugen (OCGN) – The Convert Prices, The Arb Sells, The Stock Bleeds 🔒 Paid
- 2026-05-04 UPDATE: Ocugen (OCGN) – The Fortress Gets Built (On Borrowed Bricks)
- 2026-04-27 UPDATE: Ocugen (OCGN) – The Reverse Split Cometh 🔒 Paid
- 2026-03-29 UPDATE: Ocugen (OCGN) - Phase 2 GA Data Drops – The Receipts Are In 🔒 Paid
- 2026-03-22 UPDATE: Ocugen (OCGN) – The Smart Money Shrugs Off the Delaware Drama 🔒 Paid
- 2026-03-08 UPDATE: Ocugen (OCGN) – 2025 Fiscal Year Update 🔒 Paid
- 2026-01-22 CORRECTION & UPDATE: Ocugen (OCGN) Pays the Piper
- 2026-01-21 Ocugen inc. (OCGN): Scientific Deep Dive for OCU400 and Pipeline Products
Articles open on Substack. Some deep dives are subscriber-only.